|
| Status |
Public on Apr 20, 2024 |
| Title |
Celastrol targets LRP1 to inhibit fibroblast-macrophage crosstalk and ameliorates psoriasis progression |
| Organism |
Mus musculus |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Purpose: This study aimed to explore the mechanism of Celastrol in improving psoriasis through single-cell transcriptomics
Methods: Supplementation with intragastric administration of celastrol in C57BL/6 mice to observe its effect on IMQ-induced psoriasis. Single-cell RNA sequencing were performed to explore the role of celastrol for IMQ-induced psoriasis.
Results: A natural product library was used to screen for a small molecule compound, celastrol, that could interfere with fibroblast-macrophage communication. It was demonstrated that celastrol targeted low-denisity lipoprotein receptor-related protein 1 (LRP1) to inhibit fibroblast secretion of CCL2 and inhibited psoriasis progression by reducing its recruitment to macrophages, thereby blocking communication between the two cells
Conclusion: We report that celastrol targeted low-denisity lipoprotein receptor-related protein 1 (LRP1) to inhibit fibroblast secretion of CCL2 and inhibited psoriasis progression by reducing its recruitment to macrophages. The use of celastrol maybe a noveltherapeuticoption for psoriasis.
|
| |
|
| Overall design |
Molecular mechanism of celastrol in improving psoriasis.
|
| |
|
| Contributor(s) |
Sun Y, Zhu Y, Zhang C, Qu J |
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| |
| Submission date |
May 04, 2023 |
| Last update date |
Apr 20, 2024 |
| Contact name |
Jiao Qu |
| E-mail(s) |
171850015@smail.nju.edu.cn
|
| Organization name |
Nanjing University
|
| Street address |
Nanjing University, 163 Xianlin Avenue, Nanjing 210023, China
|
| City |
Nanjing |
| ZIP/Postal code |
210023 |
| Country |
China |
| |
|
| Platforms (1) |
| GPL17021 |
Illumina HiSeq 2500 (Mus musculus) |
|
| Samples (3) |
|
| Relations |
| BioProject |
PRJNA967368 |
